Impact Biomedical Inc. filed a Form 8-K on November 17, 2026, disclosing the voting results from a special meeting of stockholders held on November 13, 2026, at which shareholders approved a merger and share exchange agreement with Zoar Limited and elected eight directors, among other matters.
Key Highlights
- Quorum reached: 7,715,210 shares, representing 89.29% of the 8,640,000 shares outstanding and eligible to vote as of the October 13, 2026 record date, were represented at the Special Meeting.
- Merger approved: Stockholders voted 7,713,011 FOR, 2,002 AGAINST, and 197 ABSTAIN to approve and adopt the Merger and Share Exchange Agreement with Zoar Limited (f.k.a Dr Ashleys Limited).
- Eight directors elected: Frank D. Heuszel, Elise Brownell, Melissa Sims, Castel Hibbert, David Keene, Christian Zimmerman, Jason Grady, and Chan Heng Fai Ambrose were each elected to serve until the next Annual Meeting.
- Auditor ratified: Grassi and Co. Certified Public Accountants, P.C. was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 7,712,827 votes FOR.
- Executive compensation approved: On an advisory basis, stockholders approved named executive officer compensation 7,506,873 FOR to 208,159 AGAINST.
- Adjournment unnecessary: The adjournment proposal was approved (7,671,841 FOR), but according to the filing, "because there were sufficient votes to approve the foregoing proposals, adjournment of the Special Meeting was not necessary."
Impact Biomedical Special Meeting: Merger Vote and Board Election Details
Impact Biomedical Inc. (NYSE American:IBO) disclosed the results of a November 13, 2026 special meeting of stockholders in a Current Report filed November 17, 2026. According to the filing, stockholders considered six proposals, all of which passed. The central matter was approval of the Merger and Share Exchange Agreement, dated June 21, 2025, as amended, among Zoar Limited (formerly Dr Ashleys Limited), a Cayman Islands exempted company; Impact Biomedical; Dr Ashleys Nevada Sub, Inc., a Nevada corporation and wholly-owned subsidiary of Zoar Limited; Zoar Labs Limited (formerly Dr Ashleys Bio Labs Limited); and Kanans Visvanats (also known as Kannan Vishwanatth), a Latvian national acting as sole stockholder of Zoar Labs Limited.
The filing notes the agreement was originally dated June 21, 2025, and subsequently amended by an amendment dated February 27, 2026, which was then rescinded and superseded by an amendment dated June 30, 2026, and further amended by an amendment dated August 13, 2026. Stockholders also approved the Amended and Restated Memorandum and Articles of Association, with 7,600,533 voting FOR, 114,489 AGAINST, and 188 ABSTAINING.
In the director election, the candidate with the highest FOR vote was Frank D. Heuszel at 7,711,539, while Chan Heng Fai Ambrose received the lowest FOR count among the eight nominees at 7,579,387. No broker non-votes were recorded for any director. The filing was signed by Frank D. Heuszel in his capacity as Chief Executive Officer on November 17, 2026.
What Was Disclosed
Impact Biomedical reported the final voting tallies from its November 13, 2026 special meeting, covering approval of a multi-party merger agreement, adoption of amended governing documents, election of eight directors, auditor ratification, and an advisory executive compensation vote.


Please wait processing your request...